Literature DB >> 26165872

Amantadine to Treat Cognitive Dysfunction in Moderate to Severe Traumatic Brain Injury.

Stephanie Stelmaschuk1, Mary Colleen Will, Tamara Meyers.   

Abstract

Traumatic brain injury (TBI) is a leading cause of injury, disability, and death in the United States. Amantadine is an established dopamine agonist that supports neurological function. The purpose of this literature review was to determine whether amantadine improves cognitive function post-TBI. PubMed and CINAHL were used to search the literature for articles using amantadine to treat TBI from 1994 to 2004. Outcomes were summarized and the evidence was appraised. Although earlier studies from 1994 to 2003 were lower-level studies and recommended further research on treatment of cognitive dysfunction in TBI, the literature from 2004 to present generally concluded that amantadine improved cognitive function related to arousal, memory, and aggression. It can be started days to months postinjury and still produces benefits.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26165872     DOI: 10.1097/JTN.0000000000000138

Source DB:  PubMed          Journal:  J Trauma Nurs        ISSN: 1078-7496            Impact factor:   1.010


  3 in total

Review 1.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

2.  Environmental enrichment and amantadine confer individual but nonadditive enhancements in motor and spatial learning after controlled cortical impact injury.

Authors:  Isabel H Bleimeister; Mia Wolff; Tracey R Lam; Derrick M Brooks; Reece Patel; Jeffrey P Cheng; Corina O Bondi; Anthony E Kline
Journal:  Brain Res       Date:  2019-03-12       Impact factor: 3.252

3.  Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial.

Authors:  Marian L Dale; Barbara H Brumbach; Adam L Boxer; Amie L Hiller
Journal:  Front Neurol       Date:  2020-12-21       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.